Brief Overview of the IOM committee on the Review of Clinical Guidance for the Care of Health Conditions Identified by the Camp Lejeune Legislation

Responding to Communities: Communicating the Science of TCE and PCE
October 20, 2015

Patricia Janulewicz Lloyd, D.Sc., M.P.H.
Boston University School of Public Health

Boston University Superfund Research Program
IOM Committee members

- David R. Nerenz, Ph.D., Committee Chair
- Robert J. Alpern, M.D.
- Paolo Boffetta, M.D., M.P.H.
- Mary E. Davis, Ph.D.
- Michael E. Goldberg, M.D.
- Paul Grundy, M.D., M.P.H., FACOEM, FACPM
- Nancy L. Keating, M.D., M.P.H.
- Patricia A. Janulewicz Lloyd, D.Sc., M.P.H.
- Gary O. Rankin, Ph.D.
- Mark J. Utell, M.D.
- Carol S. Wood, Ph.D.
- Albert W. Wu, M.D., M.P.H.
Camp Lejeune

Janey Ensminger Act, 2012

- Honoring America’s Veterans and Caring for Camp Lejeune Families Act
  - What it provides
  - Eligibility
  - VA clinical guidance
  - 15 health conditions
    - Esophageal cancer
    - Lung cancer
    - Breast cancer
    - Bladder cancer
    - Kidney cancer
    - Leukemia
    - Multiple myeloma
    - Myleodysplasic syndromes
    - Renal toxicity
    - Hepatic steatosis
    - Female infertility
    - Miscarriage
    - Scleroderma
    - Neurobehavioral effects
    - Non-Hodgkin’s lymphoma
Committee’s Task

• General Improvements
• Two specific tasks
  • Based on the latest scientific literature and the committee’s review, describe the medical conditions that result from “renal toxicity” due to solvent exposure.
  • Based on the latest scientific literature and the committee’s review, characterize the “neurobehavioral effects” as mandated for coverage in the law.
What is a Neurobehavioral Effect??
The Committee’s Decisions

• Exposure time period is a vital determinant
  • Prenatal and early Childhood exposure
    • Neurological symptoms resulting from neural tube defects
    • Adolescent and adult illicit drug use
    • Bipolar disorder
The Committee’s Decisions

• Adult Exposure
  • Parkinson’s disease
  • Symptoms or deficits in
    • Reaction time (delayed)
    • Problems with memory
    • Visuomotor function
    • Attention
    • Motor function
    • Contrast sensitivity
    • Color discrimination
Acknowledgements

IOM Committee Members
Roberta Wedge, Study director
   Cary Haver, Associate Program Officer
   Heather Chiarello, Research Associate
Roberta White, Ph.D.
Ann Aschengrau, Ph.D.
BU Superfund Program

Contact Information
Patricia Janulewicz Lloyd
paj@bu.edu
617-638-4778
1. Veteran or family members meet the applicable residency and other administrative requirements

2. Review for clinical eligibility:
   - Review of medical record, treating DOC clinical form for medical history physical exam, relevant lab test

3. Established diagnoses of cancer? (See sidebar)
   - Yes
   - No

4. Established diagnoses of scleroderma?
   - Yes
   - No

5. Documented diagnosis of infertility or miscarriage?
   - Yes
   - No

6. Established diagnoses of Chronic Kidney Disease?
   - Yes
   - No

7. Established diagnoses of Hepatic Steatosis?
   - Yes
   - No

8. Existing Neurobehavioral Symptoms?
   - Yes
   - No

9. Existing Neurobehavioral Symptoms?
   - Yes
   - No

10. Patient not accepted to the program [C-2]

Core Algorithm

Cancer Diagnoses:
- Breast cancer
- Bladder cancer
- Esophageal cancer
- Kidney cancer
- Leukemia
- Lung cancer
- Multiple myeloma
- Myelodysplastic syndromes
- Non-Hodgkin’s lymphoma
FIGURE 3-2 Algorithm B-1—Neurobehavioral outcomes in adults exposed in utero or in early childhood.

ANNOTATIONS FOR ALGORITHM B-1:

B1—Identified neurobehavioral symptoms include illicit drug use, bipolar disorder, and neurological problems associated with neural tube defects, although not all committee members were in agreement on the inclusion of illicit drug use and bipolar disorder.

B2—Applicant does not have neurobehavioral symptoms as a covered condition and is not accepted to the Camp Lejeune program at this time.

B3—Applicant accepted into the Camp Lejeune program.
FIGURE 3-1 Algorithm B—Neurobehavioral outcomes.